D
David J. Brenner
Researcher at Columbia University
Publications - 461
Citations - 37524
David J. Brenner is an academic researcher from Columbia University. The author has contributed to research in topics: Population & Biodosimetry. The author has an hindex of 77, co-authored 459 publications receiving 34516 citations. Previous affiliations of David J. Brenner include Columbia University Medical Center & University of North Carolina at Chapel Hill.
Papers
More filters
Journal ArticleDOI
Computed Tomography — An Increasing Source of Radiation Exposure
David J. Brenner,Eric J. Hall +1 more
TL;DR: The facts are summarized about CT scans, which involve much higher doses of radiation than plain films, and the implications for public health are summarized.
Journal ArticleDOI
Estimated Risks of Radiation-Induced Fatal Cancer from Pediatric CT
TL;DR: It is suggested that pediatric CT will result in significantly increased lifetime radiation risk over adult CT, both because of the increased dose per milliampere-second, and the increased lifetime risk per unit dose.
Journal ArticleDOI
Cancer risks attributable to low doses of ionizing radiation: Assessing what we really know
David J. Brenner,Richard Doll,Dudley T. Goodhead,Eric J. Hall,Charles E. Land,John B. Little,Jay H. Lubin,Dale L. Preston,R. Julian Preston,Jerome S. Puskin,Elaine Ron,Rainer K. Sachs,Jonathan M. Samet,Richard B. Setlow,Marco Zaider +14 more
TL;DR: The difficulties involved in quantifying the risks of low-dose radiation are reviewed, a linear extrapolation of cancer risks from intermediate to very low doses currently appears to be the most appropriate methodology, and a linearity assumption is not necessarily the most conservative approach.
Journal ArticleDOI
Conversion Coefficients for Use in Radiological Protection against External Radiation
Journal ArticleDOI
Fractionation and protraction for radiotherapy of prostate carcinoma
David J. Brenner,Eric J. Hall +1 more
TL;DR: High dose rate (HDR) brachytherapy would be a highly appropriate modality for treating prostate cancer because of the documented relationship between cellular proliferative status and sensitivity to changes in fractionation, and prostatic tumors contain exceptionally low proportions of proliferating cells.